A new study links high intake of ultra-processed foods (UPFs) to a 41% higher risk of lung cancer, including both NSCLC and ...

Medically reviewed by Susan Russell, MD Medically reviewed by Susan Russell, MD Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all cases. It ...

The global non-small cell lung cancer (NSCLC) market is on a robust growth trajectory, with a new report projecting its value ...

Nuvation Bio's taletrectinib shows strong efficacy in ROS1-positive NSCLC, with a 90.1% response rate. Click here to find out why NUVB stock is a Buy.

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most prevalent subtype, accounting for nearly 85% of all lung cancer cases.

Among patients with advanced or metastatic non-small cell lung cancer (NSCLC) with actionable genomic alterations, encouraging and durable antitumor activity was observed during treatment with ...

The biomarker focused Phase 1b/2 clinical trial is designed to target high-risk NSCLC subtypes by evaluating LP-184 in combination with the immune checkpoint inhibitors nivolumab and ipilimumab in ...

The study included 657 patients with EGFR-mutated NSCLC, who were randomized 2:2:1 to receive amivantamab–lazertinib–chemotherapy, chemotherapy, or amivantamab–chemotherapy.

Telisotuzumab Vedotin Approved for NSCLC With High c-Met Protein Expression M. Alexander Otto, PA, MMS May 15, 2025 0 ...

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need Drug candidate LP-184 to be ...